Biomarin Pharmaceutical Inc. - Registered Shares
BMRN
Get informed when a big investor buys or sells
+ FollowTarget Price by Analysts
65% upsideBiomarin Pharmaceutical - Registered Shares Target Price Details
Current Fair Value
143.5% upsideUndervalued by 143.5% based on the discounted cash flow analysis.
Share Statistics
| Market cap | $11.07 Billion |
|---|---|
| Enterprise Value | $10.29 Billion |
| Dividend Yield | $- (-) |
| Earnings per Share | $1.82 |
| Beta | 0.23 |
| Outstanding Shares | 192,497,000 |
Return
| Return on Equity | 4.33% |
|---|---|
| Return on Assets | 3.13% |
| Return on Invested Capital | 5.17% |
Valuation & Multiples
| P/E Ratio | 41.04 |
|---|---|
| PEG | -95.06 |
| Price to Sales | 3.42 |
| Price to Book Ratio | 1.71 |
| Enterprise Value to Revenue | 3.17 |
| Enterprise Value to EBIT | 25.52 |
| Enterprise Value to Net Income | 38 |
| Total Debt to Enterprise | 0.14 |
| Debt to Equity | 0.23 |
Revenue Sources
No data
Insider Trades
Last Earnings Call
Next Earnings Call
Institutional Put/Call Ratio
Market sentiment based on institutional option activity.
| Put/Call Ratio | 0.7374▲ 12.74% |
|---|---|
| Total Calls | 1,490,196▼ 15.04% |
| Total Puts | 1,098,900▲ 2.70% |
Institutional Ownership
Holdings and activity of institutional investors.
| Ownership % | 95.72%▼ 2.47% |
|---|---|
| Total Invested | $10.36B▼ 7.30% |
| Investors Holding | 575▲ 5.00% |
ESG Score
No data
About Biomarin Pharmaceutical Inc.
CEO: Jean-Jacques Bienaime Relevant Senate Committees
Controls taxation, trade, and entitlement spending (Medicare/Medicaid). This committee directly impacts pharmaceutical companies through tax policy, and significantly through drug pricing and reimbursement under federal healthcare programs.
Allocates discretionary federal spending. Its subcommittees determine the precise funding for agencies like the FDA and NIH, as well as healthcare programs (Medicare/Medicaid), directly impacting the R&D and market for pharmaceutical companies.
Regulates the FDA and NIH. This committee directly influences drug approval processes, research funding, and labor laws, all of which are critical to the operations and success of a pharmaceutical company like Biomarin.
Oversees the DOJ, antitrust laws, and intellectual property. Patent law (IP) is fundamental to pharmaceutical companies, and antitrust oversight directly impacts potential mergers and market practices within the sector.
Investigates issues affecting older Americans, including drug pricing and healthcare costs. Its hearings and reports directly create headline risk and influence policy discussions crucial to pharmaceutical company valuations.